Rob Woodman is Director of Healthcare Investments at Touchstone Innovations. In addition to PsiOxus, Rob currently serves on the boards of Mission Therapeutics, Crescendo Biologics, Inivata, Storm Therapeutics, Enterprise Therapeutics and Nascient Therapeutics. He joined Innovations in 2012 and was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Whilst at Sofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRUK) through to pharmaceutical consultancy with IMS Health. He holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge. Rob Woodman is Director of Healthcare Investments at Touchstone Innovations. In addition to PsiOxus, Rob currently serves on the boards of Mission Therapeutics, Crescendo Biologics, Inivata, Storm Therapeutics, Enterprise Therapeutics and Nascient Therapeutics. He joined Innovations in 2012 and was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Whilst at Sofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRUK) through to pharmaceutical consultancy with IMS Health. He holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.

fermentation